Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Net Income (2016 - 2025)

Historic Net Income for Ani Pharmaceuticals (ANIP) over the last 15 years, with Q3 2025 value amounting to $26.6 million.

  • Ani Pharmaceuticals' Net Income rose 21007.2% to $26.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.5 million, marking a year-over-year increase of 67156.96%. This contributed to the annual value of -$18.5 million for FY2024, which is 19863.15% down from last year.
  • As of Q3 2025, Ani Pharmaceuticals' Net Income stood at $26.6 million, which was up 21007.2% from $8.5 million recorded in Q2 2025.
  • Ani Pharmaceuticals' Net Income's 5-year high stood at $26.6 million during Q3 2025, with a 5-year trough of -$24.2 million in Q3 2024.
  • Moreover, its 5-year median value for Net Income was -$2.3 million (2024), whereas its average is -$2.1 million.
  • As far as peak fluctuations go, Ani Pharmaceuticals' Net Income plummeted by 1837272.73% in 2022, and later skyrocketed by 113521.03% in 2024.
  • Over the past 5 years, Ani Pharmaceuticals' Net Income (Quarter) stood at -$24.1 million in 2021, then soared by 82.35% to -$4.3 million in 2022, then soared by 127.12% to $1.2 million in 2023, then plummeted by 989.7% to -$10.3 million in 2024, then soared by 358.86% to $26.6 million in 2025.
  • Its Net Income was $26.6 million in Q3 2025, compared to $8.5 million in Q2 2025 and $15.7 million in Q1 2025.